Tiziana Life Sciences (US) (TLSA) has released an update.
Tiziana Life Sciences has received FDA approval to expand their intranasal foralumab Expanded Access Program for Secondary Progressive Multiple Sclerosis, increasing the number of patients from 10 to 30. This program offers access to a novel treatment for patients not eligible for a concurrent Phase 2a trial, with the existing participants showing stabilization or improvement in clinical measures and reduced fatigue. The company emphasizes the potential of their fully human anti-CD3 monoclonal antibody to modulate immune responses and provide a new treatment avenue for neuroinflammatory conditions.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
